Literature DB >> 3335296

In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease.

G de Ritis1, S Auricchio, H W Jones, E J Lew, J E Bernardin, D D Kasarda.   

Abstract

Specific peptides of known amino acid sequence were prepared from alpha-gliadin (A-gliadin) by cleavage of the protein with cyanogen bromide and chymotrypsin and purification of the resulting peptides. The three peptides derived from the cyanogen bromide cleavage spanned the complete sequence of A-gliadin (266 residues). Four peptides derived from chymotryptic digestion covered the N-terminal sequence through residue 68. These peptides were tested for toxicity in celiac disease by organ culture of biopsied small intestinal tissues taken from patients with active celiac disease. Enterocyte height was used as a measure of peptide effect on cultured tissues. Five of seven peptides tested significantly inhibited increase of enterocyte height in the cultures and were considered toxic on this basis. The largest common sequences among the toxic peptides were -pro-ser-gln-gln- and -gln-gln-gln-pro-; these sequences were absent from the nontoxic peptides. The relationship of these sequences to the damaging effect of gliadins on the small intestinal mucosa in celiac disease remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335296     DOI: 10.1016/0016-5085(88)90607-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  31 in total

1.  Getting to grips with gluten.

Authors:  S N McAdam; L M Sollid
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

Review 2.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Cereal chemistry, molecular biology, and toxicity in coeliac disease.

Authors:  R P Sturgess; H J Ellis; P J Ciclitira
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

4.  Conformational studies of peptides corresponding to the coeliac-activating regions of wheat alpha-gliadin.

Authors:  A S Tatham; M N Marsh; H Wieser; P R Shewry
Journal:  Biochem J       Date:  1990-09-01       Impact factor: 3.857

5.  Coeliac disease: A review of the causative agents and their possible mechanisms of action.

Authors:  H J Cornell
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

6.  Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease.

Authors:  S Krupicková; L Tucková; Z Flegelová; M Michalak; J R Walters; A Whelan; J Harries; J Vencovský; H Tlaskalová-Hogenová
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

7.  Studies on the interaction between alpha-gliadin and HLA and T cell receptor molecules in coeliac disease.

Authors:  R B Gallagher; C Feighery; D G Weir; C P Kelly; C A Whelan
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

8.  Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin.

Authors:  M ten Dam; Y Van De Wal; M L Mearin; Y Kooy; S Peña; J W Drijfhout; F Koning; M Van Tol
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin.

Authors:  Y van de Wal; Y M Kooy; P A van Veelen; S A Peña; L M Mearin; O Molberg; K E Lundin; L M Sollid; T Mutis; W E Benckhuijsen; J W Drijfhout; F Koning
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes.

Authors:  Siri Dørum; Magnus Ø Arntzen; Shuo-Wang Qiao; Anders Holm; Christian J Koehler; Bernd Thiede; Ludvig M Sollid; Burkhard Fleckenstein
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.